Adverse thrombo-embolic events with newer tyrosine kinase inhibitors: a call to action for better risk stratification and monitoring
Hussain Z, Baldassarre L, Dent S, Weintraub NL, Guha A. Adverse thrombo-embolic events with newer tyrosine kinase inhibitors: a call to action for better risk stratification and monitoring. European Journal Of Preventive Cardiology 2021, 29: 1309-1311. PMID: 34219160, DOI: 10.1093/eurjpc/zwab055.Peer-Reviewed Original ResearchHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsRisk AssessmentTaiwanThromboembolism